



UNITED STATES PATENT AND TRADEMARK OFFICE

J.C.

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/658,734	09/11/2000	Winfried Edelmann	AHN-001DV1	9039
959	7590	11/30/2004	EXAMINER	
LAHIVE & COCKFIELD, LLP. 28 STATE STREET BOSTON, MA 02109			DAVIS, RUTH A	
			ART UNIT	PAPER NUMBER
			1651	
DATE MAILED: 11/30/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/658,734	Applicant(s) EDELMANN ET AL.	
	Examiner Ruth A. Davis	Art Unit 1651	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 September 2004.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 13,24 and 29-71 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 13,24,29-71 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 - 1. Certified copies of the priority documents have been received.
 - 2. Certified copies of the priority documents have been received in Application No. _____.
 - 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

Art Unit: 1651

DETAILED ACTION

Applicant's amendment and response filed September 3, 2004 has been received and entered into the case. Claims 13, 24, and 29 – 71 are pending and have been considered on the merits. All arguments have been fully considered.

Claim Rejections - 35 USC § 112

Rejections under 35 U.S.C. 112, second paragraph, have been withdrawn due to amendment.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Art Unit: 1651

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 13, 24 and 29 – 71 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Fishel in view of Hollingsworth.

Applicant claims methods for identifying compounds useful as a contraceptive, for inhibiting meiosis, preventing fertilization, inhibiting and stimulating chromosome synapsis. The methods comprise contacting MSH5 or a cell expressing MSH5 with the compound, determining activity or expression of MSH5 in the presence of the compound, selecting a compound that inhibits MSH5, and identifying the compound useful for a contraceptive, inhibiting meiosis, preventing fertilization and inhibiting chromosome synapsis (or stimulating MSH5 for stimulating chromosome synapsis). The compound may be an antisense MSH5 nucleic acid, inhibitor of MSH5 substrate activity, a small molecule, MSH5 antibody, peptide or peptidomimetic.

Fishel teaches a method for determining if a composition (test compound) affects (or modulates) expression of a gene encoding a MutS homolog (MSH) (col.9 line 10-15) wherein the MutS homolog is MSH5 (col.4 line 35-40). The method comprises administering the test composition (or compound) to a cell containing the MutS homolog (or MSH5) and determining the activity or expression of the MutS homolog to determine if the compound effects (or modulates) MutS homolog activity (col.9 line 29-45).

Fishel does not teach the method wherein the compound is useful to inhibit meiosis, prevent fertilization, as a contraceptive, or to inhibit/stimulate chromosome synapsis. However,

Art Unit: 1651

Hollingsworth teaches that MSH5 is a meiosis specific gene, active to facilitate meiosis and meiotic chromosome synapsis (abstract) in bacteria, yeast and humans (p.1729). Hollingsworth additionally teaches that mutant MSH5 (or inhibited activity thereof) results in decreased spore (or gamete) viability (p.1735, 1736). Moreover, Hollingsworth suggests that inhibited or reduced activity of MSH5 inhibits meiosis, chromosome synapsis and decreases fertility. At the time of the claimed invention, it would have been obvious to one of ordinary skill in the art to use inhibitors of MSH5 activity identified by the methods of Fishel, as inhibitors of meiosis, chromosome synapsis and fertility, since the gene was known to facilitate these activities. It would have been further obvious to one of ordinary skill in the art to identify the inhibitors useful for contraceptive agents, since it was well known in the art that meiosis, chromosome synapsis and fertility are required for conception. Moreover, at the time of the claimed invention, one of ordinary skill in the art would have been motivated by the teachings of Hollingsworth to use the identified compounds of Fishel, as inhibitors of meiosis, fertilization and chromosome synapsis, as well as contraceptive agents.

Fishel does not teach the method wherein the compound may be any of the claimed types of compounds. However, at the time of the claimed invention, it would have been obvious to one of ordinary skill in the art to use any compound in the method of Fishel, since the method is directed to determining the effects of compounds (any compound) on MSH5. It would have been well within the purview of one of ordinary skill in the art to use any compound in the method, since the method is specifically directed to testing compounds for their effect on MSH5. Moreover, at the time of the claimed invention, one of ordinary skill in the art would have been

Art Unit: 1651

motivated by routine practice to use any type of compound in the methods of Fischel with a reasonable expectation for successfully determining the effect of a compounds on MSH5.

Response to Arguments

Applicant argues that the references do not teach the relationship between MSH5 and meiosis or contraception; and has submitted affidavits stating that the invention was conceived prior to October 1, 1998. Applicant additionally argues that the references do not teach a relationship of MSH5 and mice or mammals.

However, these arguments fail to persuade because Hollingsworth (1995) specifically teaches a direct relationship of MSH5 to meiosis and chromosome synapsis in yeast, bacteria and humans (prior to October 1, 1998). In addition, it is noted that the affidavits filed on January 27, 2004 under 37 CFR 1.131 are not signed, and are therefore defective. Finally, it is noted that the instant claims do not require a particular animal or mammal, thus the arguments are not commensurate in scope with the claimed invention.

Conclusion

4. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO**

Art Unit: 1651

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruth A. Davis whose telephone number is 571-272-0915. The examiner can normally be reached on M-H (7:00-4:30); altn. F (7:00-3:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ruth A Davis
November 24, 2004
AU 1651



LEON B. LANKFORD, JR.
PRIMARY EXAMINER